Key Insights

Highlights

Treatment Research

12 treatments under study, led by Ct Perfusion

Research Leaders

15 sponsors active, led by Stanford University

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

40.0%

4 terminated out of 10 trials

Success Rate

20.0%

-66.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Recruiting4
Terminated4
Withdrawn1
Completed1

Trial Success Rate

20.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06252753RecruitingPrimary

Observational Study Protocol: LIVER-R

NCT06549829Not ApplicableCompleted

the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma

NCT07142213Recruiting

Effect and Mechanism of ALPPS Operation on Liver Regeneration

NCT06835426Not ApplicableRecruiting

High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins

NCT06777914RecruitingPrimary

Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers

NCT01163526Terminated

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

NCT00767936Terminated

Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma

NCT01071434Terminated

Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors

NCT01031056Withdrawn

Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers

NCT00768001Terminated

Genetic Analysis of Liver Cancer

Showing all 10 trials

Research Network

Common Treatments

  • Ct Perfusion1
  • Non Durvalumabbased Therapies In Observational Study Setting1
  • Nutritional Optimizationled Triple Prehabilitation Intervention1
  • Durvalumabbased Combination Therapies In Observational Study Settings1
  • Single Intravenous Injection Of The Radiotracer1

Active Sponsors

  • Stanford University4
  • Haitao Zhao, MD1
  • Samuel So1
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna1
  • Second Affiliated Hospital, Zhejiang University, School of Medicine1

Top Investigators

Related Conditions

  • Liver Cancer4
  • Hepatobiliary Cancers Liver4
  • Pancreatic Cancer2
  • Hepatitis C2
  • Hepatitis B2

Activity Timeline